FF301 致：香港交易及結算所有限公司 公司名稱: 山東新華製藥股份有限公司 呈交日期: 2025年8月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00719 | 說明 | H股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 195,000,000 | RMB | | 1 | RMB | | 195,000,000 | | 增加 / 減少 (-) | | | | | | | RMB | | | | 本月底結存 | | | 195,000,000 | RMB | | 1 | RMB | | 195,000,000 | | 2. 股份分類 | 普通股 | 股份類別 | A | | 於香港聯交所上市 (註1) | | 否 | | | --- | --- | --- | ...

智通财经APP获悉，根据2025年7月31日披露数据，锦欣生殖（01951）、长飞光纤光缆（06869）、美 中嘉和（02453）港股通持股占比增加值最大，分别增加2.58%、2.38%、2.29%；上海復旦（01385）、 山东新华製药股份（00719）、钧达股份（02865）港股通持股占比减少值最大，分别减 少-1.70%、-1.37%、-1.25%。 在最近有统计数据的5个交易日内，宜搜科技（02550）、长飞光纤光缆（06869）、恆生中国企业 （02828）港股通持股占比增加值最大，分别增加14.75%、11.72%、7.36%；山东新华製药股份 （00719）、亚盛医药-B（06855）、重庆钢铁股份（01053）港股通持股占比减少值最大，分别减 少-3.89%、-2.94%、-2.70%。 具体数据如下（交易所数据根据T+2日结算）： 1、港股通最新日占比增持榜（前20名） | 公司名称 | 占比值变动 | 最新持股比例 | | --- | --- | --- | | 锦欣生殖(01951) | +2.58% | 51.76% | | 长飞光纤光缆(06869) | +2.38% | 44.07 ...

Core Insights - The article highlights the changes in the Hong Kong Stock Connect holdings, indicating which companies have seen the largest increases and decreases in shareholding percentages. Group 1: Increased Holdings - Changfei Optical Fiber Cable (06869) saw the largest increase in holdings, up by 3.06% to a total holding of 41.69% [1][2] - Kanglong Chemical (03759) increased by 2.36%, reaching a holding of 54.24% [1][2] - Yisou Technology (02550) rose by 1.80%, with a current holding of 58.01% [1][2] - Other notable increases include China Zhongjin (01880) with a 0.78% increase to 41.73% and Shanghai Electric (02727) with a 0.76% increase to 43.36% [2] Group 2: Decreased Holdings - Shandong Xinhua Pharmaceutical (00719) experienced the largest decrease, down by 1.74% to a holding of 46.02% [1][3] - Southern Hengsheng Technology (03033) decreased by 0.95%, now holding 61.82% [1][3] - Jihong Co., Ltd. (02603) saw a reduction of 0.91%, with a current holding of 37.85% [1][3] - Other significant decreases include Junshi Biosciences (01877) down by 0.76% to 50.62% and New China Life Insurance (01336) down by 0.71% to 53.23% [3][4] Group 3: Five-Day Changes - Over the last five trading days, Yisou Technology (02550) had the highest increase of 13.77%, reaching 58.01% [5] - Changfei Optical Fiber Cable (06869) increased by 9.53% to 41.69% [5] - The Hang Seng China Enterprises Index (02828) rose by 5.73%, now at 7.19% [5] - Other notable increases include China Energy Construction (03996) up by 5.39% to 21.41% [5] Group 4: Twenty-Day Changes - In the last twenty days, Haotian International Construction (01341) saw the largest increase of 33.88%, reaching 59.80% [8] - Jihong Co., Ltd. (02603) increased by 26.53% to 37.85% [8] - Yisou Technology (02550) rose by 19.75% to 58.01% [8] - Other significant increases include Oriental Electric (01072) up by 15.27% to 43.05% [8] Group 5: Summary of Trends - The data indicates a trend of increasing foreign investment in certain technology and pharmaceutical companies, while traditional sectors like pharmaceuticals and steel are experiencing reductions in foreign holdings [1][5][8]

Core Viewpoint - Shandong Xinhua Pharmaceutical Co., Ltd. actively participated in a voluntary blood donation campaign, demonstrating corporate social responsibility and employee engagement [1] Group 1: Company Initiatives - The company organized a blood donation event involving its first and second plants and the security department, showcasing a collective effort to contribute to society [1] - A total of 103 employees participated in the blood donation, contributing 38,450 milliliters of blood, highlighting the company's commitment to social causes [1] Group 2: Employee Engagement - Employees expressed a sense of fulfillment and purpose in donating blood, with one employee mentioning he has donated four times and plans to continue annually [1] - The event fostered a sense of community and solidarity among employees, reinforcing the company's internal cohesion and shared values [1]

金融界消息 截至2025年7月30日收盘，新华制药（000756）报收于17.07元，下跌0.93%，换手率 5.31%，成交量26.18万手，成交金额4.51亿元。 天眼查商业履历信息显示，山东新华制药股份有限公司，成立于1998年，位于淄博市，是一家以从事医 药制造业为主的企业。企业注册资本689776.535万人民币，实缴资本68240.7635万人民币。公司法定代 表人为贺同庆。 通过天眼查大数据分析，山东新华制药股份有限公司共对外投资了19家企业，参与招投标项目5000次， 知识产权方面有商标信息402条，专利信息521条，此外企业还拥有行政许可855个。 资金流向方面，今日主力资金净流出1505.43万元，占比成交额3.34%。其中，超大单净流出1225.38万 元、占成交额2.72%，大单净流出280.05万元、占成交额0.62%，中单净流出流出1216.33万元、占成交 额2.7%，小单净流入2721.75万元、占成交额6.04%。 新华制药最新一期业绩显示，截至2025一季报，公司营业总收入24.30亿元、同比减少1.81%，归属净利 润1.12亿元，同比减少20.99%，扣非净利润1.05 ...

（文章来源：证券日报） 证券日报网讯新华制药7月29日在互动平台回答投资者提问时表示，公司是全球解热镇痛类药物主要生 产商之一，公司产品名录请参见公司官网。 ...

证券日报网讯新华制药7月29日在互动平台回答投资者提问时表示，公司围绕心脑血管类、解热镇痛 类、消化系统类、抗代谢类、神经系统等12个方向开展研发工作，包括创新药物和仿制药。进入研发管 线的药物有100多个。在创新药领域已构建多个大研发平台（如新型给药系统、小分子创新等），在研 产品包括进入Ⅱ期临床的OAB14（用于阿尔茨海默病治疗）等多个创新药物进展顺利。 （文章来源：证券日报） ...

Core Viewpoint - The article discusses the challenges and opportunities faced by Xinhua Pharmaceutical as it enters the competitive market for the drug Maleate Avatrombopag, highlighting its recent licensing change and the pressures on its financial performance and R&D efforts [2][12]. Financial Performance - In 2024, Xinhua Pharmaceutical reported a revenue of 8.466 billion yuan, a year-on-year increase of 4.51%, marking a historical high, but its net profit fell by 5.33% to 470 million yuan, indicating a "revenue increase without profit increase" phenomenon for the first time since 2013 [7][11]. - The company's revenue sources in 2024 included 4.072 billion yuan from formulations, 2.736 billion yuan from chemical raw materials, and 1.658 billion yuan from intermediates, with significant declines in gross margins across these categories [7][11]. - In Q1 2025, Xinhua's revenue was 2.43 billion yuan, down 1.81% year-on-year, and net profit decreased by 20.99% to 112 million yuan [8]. R&D Investment - Xinhua's total R&D investment in 2024 was 397 million yuan, a decrease of 2.23% from the previous year, with R&D expenditure accounting for 4.69% of revenue, down 0.32 percentage points [9][12]. - Despite a reduction in R&D spending, the company achieved several product approvals, including 7 products with 9 specifications receiving consistency evaluation [8][9]. Market Competition - The market for Maleate Avatrombopag is highly competitive, with 18 companies, including Fosun Pharma and others, vying for market share through price competition and channel expansion [4][5]. - The original drug, Su Ke Xin® by Fosun Pharma, has a first-mover advantage and has been included in the national medical insurance catalog, further intensifying competition [4][5]. Strategic Opportunities - Xinhua's acquisition of the Maleate Avatrombopag marketing license is seen as a potential opportunity to enhance its product portfolio in blood system disease medications and improve its competitive edge [12]. - The company needs to focus on optimizing its product structure and increasing R&D investment to maintain innovation and competitiveness in the market [12].

证券代码：000756 证券简称：新华制药 公告编号： 2025-44 山东新华制药股份有限公司 关于子公司产品获得三类医疗器械注册证的公告 山东新华制药股份有限公司（以下简称"公司"）之子公司山东新华健康科技有限公司 近日收到国家药品监督管理局颁发的《中华人民共和国医疗器械注册证》，具体情况如下： 一、医疗器械注册证的具体情况 1、产品名称：接触镜无菌生理盐水护理液 2、注册证编号：国械注准 20253161329 3、注册人名称：山东新华健康科技有限公司 4、注册人住所：山东省淄博市高新区鲁泰大道 1 甲 1 号 5、受托生产企业：山东新华制药股份有限公司 生产地址：山东省淄博市高新区兰雁大道 3 号（委托生产）、山东省淄博市高新区鲁泰 大道 1 号（委托生产）。 6、结构及组成：该产品为含有 0.9%氯化钠的无菌生理盐水溶液，由氯化钠和注射用水 组成。产品经湿热灭菌，一次性使用。货架有效期 12 个月。 7、型号、规格：10ml、20ml 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导 性陈述或重大遗漏。 11、同类产品相关情况：根据国家药品监督管理局官网数据查询信息，截至 ...

Summary of Key Points Core Viewpoint - As of July 11, a total of 167 stocks reached their 52-week highs, indicating a strong market performance with notable leaders in the stock price increases [1]. Group 1: Top Performing Stocks - The top three stocks with the highest increase rates are: - Mistrategy Equity (02902) with a high rate of 67.86% and a closing price of 1.600 [1] - Kexuan Power Holdings (00476) with a high rate of 58.73% and a closing price of 1.000 [1] - Xingzheng International (06058) with a high rate of 36.00% and a closing price of 0.590 [1] Group 2: Notable Stock Performance - Other notable stocks include: - China National Cultural Industry (00745) with a high rate of 34.62% [1] - Aluminum Corporation of China International (02068) with a high rate of 28.21% [1] - Shandong Xinhua Pharmaceutical (00719) with a high rate of 13.20% [1] Group 3: Additional Stocks with Significant Increases - Additional stocks with significant increases include: - Yuyuan Agriculture (09858) with a high rate of 12.62% [1] - WuXi AppTec (02359) with a high rate of 11.70% [1] - Kailai Ying (06821) with a high rate of 10.90% [1] Group 4: 52-Week Low Rankings - The 52-week low rankings show: - XI II Nan CO (07311) with a low rate of -12.60% [5] - XI II Nan Strategy (07399) with a low rate of -11.18% [5] - Ying Tai Medical (01501) with a low rate of -10.67% [5]